Lifesci Capital Initiates Coverage on Lycia Therapeutics (NASDAQ:LYCA)

Lifesci Capital initiated coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Get Free Report) in a report issued on Tuesday, Benzinga reports. The firm set an “outperform” rating and a $48.00 price target on the stock. Lifesci Capital‘s price target suggests a potential upside of 54.44% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Evercore initiated coverage on Lycia Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $43.00 price objective on the stock. Wall Street Zen upgraded Lycia Therapeutics to a “hold” rating in a research report on Saturday, October 31st. Guggenheim assumed coverage on Lycia Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $75.00 target price on the stock. Jefferies Financial Group initiated coverage on Lycia Therapeutics in a report on Tuesday. They issued a “buy” rating and a $50.00 price target on the stock. Finally, TD Cowen initiated coverage on Lycia Therapeutics in a research report on Tuesday. They set a “buy” rating for the company. Five research analysts have rated the stock with a Buy rating. According to MarketBeat.com, Lycia Therapeutics presently has a consensus rating of “Buy” and an average target price of $54.00.

Check Out Our Latest Stock Report on LYCA

Lycia Therapeutics Price Performance

NASDAQ:LYCA traded up $0.16 during trading hours on Tuesday, hitting $31.08. The stock had a trading volume of 286,039 shares, compared to its average volume of 333,076. Lycia Therapeutics has a one year low of $22.19 and a one year high of $36.49.

Insider Activity

In related news, major shareholder Venrock Healthcare Capital Par acquired 8,305 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was bought at an average cost of $26.95 per share, with a total value of $223,819.75. Following the acquisition, the insider owned 6,858,542 shares of the company’s stock, valued at approximately $184,837,706.90. The trade was a 0.12% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have acquired 2,078,749 shares of company stock worth $38,526,342.

Lycia Therapeutics Company Profile

(Get Free Report)

Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.

Further Reading

Analyst Recommendations for Lycia Therapeutics (NASDAQ:LYCA)

Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.